Find the right fit for you - faster
Get tailored insights about working at SyntheMed in one quick step.
SyntheMed Snapshot
Pathfinder Cell Therapy (formerly SyntheMed) keeps surgery patients and disease sufferers off the path towards scarring and organ damage. The company develops polymers aimed at preventing or reducing post-operative adhesions (scar tissue) for a variety of surgical procedures. Its REPEL-CV product, used to prevent the formation of scar tissue in open heart surgeries, is marketed internationally and is approved for use in pediatric cardiac surgeries in the US. The firm added development-stage tissue regeneration products for diabetics and others at risk of organ damage through its 2011 merger with biotech firm Pathfinder LLC; its name changed from SyntheMed to Pathfinder Cell Therapy following the merger.
